Allogene Therapeutics Acknowledges the Passing of Founding Board Member David BondermanGlobeNewsWire • 12/12/24
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?Zacks Investment Research • 12/02/24
Allogene Therapeutics Announces Participation in December Investor ConferencesGlobeNewsWire • 11/19/24
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) ConvergenceGlobeNewsWire • 11/18/24
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdateGlobeNewsWire • 11/07/24
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCSGlobeNewsWire • 11/07/24
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 11/05/24
Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 10/31/24
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business UpdateGlobeNewsWire • 10/30/24
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day ConferenceGlobeNewsWire • 09/30/24
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/06/24
Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell TherapiesSeeking Alpha • 08/27/24
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business UpdateGlobeNewsWire • 08/07/24
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business UpdateGlobeNewsWire • 07/31/24
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)GlobeNewsWire • 07/01/24
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to RelapseGlobeNewsWire • 06/20/24
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T ProductsSeeking Alpha • 06/12/24